Genmab — December 2020
-
Nogen der kan læse det her? Lyder
spændende: https://ugebrev.dk/life-science/selskabsanalyser/genmab-mod-nye-hoejder-i-det-nye-aar/?mc_cid=115bcdb3b5&mc_eid=5805bdd5ee -
GENMAB – mod nye højder i det nye år!
Af David Mygind d. 18/12
Forventningerne til dette års ASH-konference var skyhøje, men der blev leveret som ventet, og der er nu linet op til et kapløb mellem Genmab og Roche indenfor de bi-specifikke antistoffer i NHL. Efter lidt konsolidering omkring det nuværende kursleje virker aktien nu klar til at bevæge sig op i nye højder i det nye år. … -
God morgen.
-
En vel i dag
endnu mere aktuel artikel fra 2016, sjovt her i slutningen af 2020 at læse den igen: https://www.proinvestor.com/boards/74456 -
Epcoritamab has entered the EMA paper-mountain... 3.1.40. Epcoritamab - EMEA-002907-PIP01-20
Treatment of mature B-cell lymphoma / Treatment of paediatric patients with
relapsed/refractory aggressive mature B-cell lymphoma
Day 30 discussion
Action: For discussion
Oncology https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-8-11-december-2020-meeting_en.pdf -
God morgen.
-
Mandagens aviser med Pandora, Mærsk og Danske Bank: https://www.proinvestor.com/investornyt/670532/mandagens-aviser-med-pandora-maersk-og-danske-bank
-
Aktier/tendens: Fokus på fredagens
trækheste i ventet rød åbning. https://www.proinvestor.com/investornyt/670538/aktier-tendens-fokus-pa-fredagens-traekheste-i-ventet-rod-abning -
This case emphasizes that, with the availability of novel immunotherapy agents (Daratumumab), and repurposed use of bortezomib, a patient with HIV‐negative relapsed PBL can be treated successfully https://onlinelibrary.wiley.com/doi/10.1002/ccr3.3673
-
Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication https://endpts.com/best-selling-tagrisso-further-outpaces-an-upcoming-jj-rival-winning-approval-in-new-nsclc-indication/
-
Why GPRC5D is a promising target for multiple myeloma https://multiplemyelomahub.com/medical-information/why-gprc5d-is-a-promising-target-for-multiple-myeloma
-
New trial - Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis (TIMIOS) https://clinicaltrials.gov/ct2/show/NCT04676555
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind